L.B. van Rijssen | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where L.B. van Rijssen is active.

Explore More

Publication

Featured researches published by L.B. van Rijssen.

Annals of Surgical Oncology | 2017

Skeletal Muscle Quality is Associated with Worse Survival After Pancreatoduodenectomy for Periampullary, Nonpancreatic Cancer.

L.B. van Rijssen; N. van Huijgevoort; R. Coelen; Johanna A. M. G. Tol; E. Haverkort; C. Y. Nio; Olivier R. Busch; Marc G. Besselink

Pancreatology | 2018

Intra-operative ultrasound to determine resectability during surgical exploration of primary non-resectable pancreatic cancer following induction chemotherapy

Marieke S. Walma; Eran van Veldhuisen; L.B. van Rijssen; Olivier R. Busch; Rutger C. G. Bruijnen; Otto M. van Delden; Nadia Haj Mohammad; Ignace H. de Hingh; Lonneke S. Yo; Hanneke W. M. van Laarhoven; Maarten S. van Leeuwen; Chung Yung Nio; Hjalmar C. van Santvoort; Jan de Vries; Frank J. Wessels; J.W. Wilmink; I.Q. Molenaar; Marc G. Besselink; Krijn P. van Lienden

Hpb | 2018

Additional value of 3d-vision during laparoscopic pancreatoduodenectomy bio tissue drills (LAELAPS 3D2D): A randomized controlled cross-over trial

Maurice J. Zwart; J. van Hilst; I.P. Fuente; T. de Rooij; S. van Dieren; L.B. van Rijssen; M.P. Schijven; O.R.C. Busch; Misha D. Luyer; D.J. Lips; Sebastiaan Festen; M.G. Besselink

Hpb | 2018

Intra-operative ultrasound to determine resecability during surgical exploration of primary non-resectable pancreatic cancer following induction chemotherapy

E. van Veldhuisen; Marieke S. Walma; L.B. van Rijssen; O.R.C. Busch; H.W.M. van Laarhoven; M. S. van Leeuwen; J.W. Wilmink; I.Q. Molenaar; M.G. Besselink; K.P. van Lienden

Hpb | 2018

Outcomes of pancreatoduodenectomy in the German DGAV StuDoQ|Pancreas registry - a cross-validation study with the Dutch pancreatic cancer audit

Tara Mackay; Ulrich F. Wellner; L.B. van Rijssen; Tf Stoop; O.R.C. Busch; B. Groot Koerkamp; Dirk Bausch; Ekaterina Petrova; M.G. Besselink; Tobias Keck

Annals of Oncology | 2017

745PCirculating levels of ADAM12, a stromal activation biomarker, are predictive of survival in pancreatic ductal adenocarcinoma (PDAC)

H.W.M. van Laarhoven; Helene Damhofer; Veronique L. Veenstra; Cynthia Waasdorp; L.B. van Rijssen; F. Dijk; J.W. Wilmink; M.G. Besselink; O.R.C. Busch; Jan Paul Medema; J. Shiansong Li; R. Jiang; D.W. Pierce; Maarten F. Bijlsma

Annals of Oncology | 2017

Consensus statement on mandatory measurements in Pancreatic cancer trials for systemic treatment of unresectable disease (COMMPACT)

L.B. van Rijssen; E. ter Veer; M.G. Besselink; Rosa M A Mali; Jordan Berlin; Stefan Boeck; Franck Bonnetain; Thierry Conroy; Gael Deplanque; David Goldstein; Bengt Glimelius; John P. Neoptolemos; Michele Reni; Werner Scheithauer; J. van der Meer; J.W. Wilmink; M.J. van der Poel; O.R.C. Busch; M. G. H. van Oijen; H.W.M. van Laarhoven

Annals of Oncology | 2017